Altimmune (ALT) Stock News Today (Dec. 17, 2025): Pemvidutide Catalysts, CEO Transition, and Wall Street Price Targets
Altimmune shares traded near $5.03 early Wednesday after closing at the same level Tuesday, with volatility elevated ahead of a key clinical update expected by year-end. The company’s valuation hinges on pemvidutide’s 48-week IMPACT Phase 2b readout for MASH, due in Q4 2025. Leadership changes and wide analyst price targets have added to market uncertainty. The stock jumped 12% intraday on Dec. 12 before retreating.